Determinants of antipsychotic polypharmacy in psychiatric inpatients: A prospective study

International Clinical Psychopharmacology

Volumn 20, Issue 6, 2005, Pages 305-309

  Biancosino, Bruno ^a,b   Barbui, Corrado ^c   Marmai, Luciana ^a,b   Donà, Silna ^a,b   Grassi, Luigi ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b Local Health Agency   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Antipsychotic combination therapy; Antipsychotics; Drug therapy combination; Inpatient

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG MEGADOSE; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSTILITY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL DISEASE; MENTAL PATIENT; POLYPHARMACY; PRIORITY JOURNAL; SOCIAL ASPECT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; INPATIENTS; ITALY; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 26944460800     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200511000-00004     Document Type: Article

References (16)

1. Barbui C, Tansella M (2005). Psychotropic drug epidemiology: the road travelled, the road ahead. Int Rev Psychiatry, in press.
2. Biancosino B, Barbui C, Pera V, Osti M, Rocchi D, Marmai L, Grassi L (2004). Patient opinions on the benefits of treatment programs in residential psychiatric care. Can J Psychiatry 49:613-620.
3. Canales PL, Olsen J, Miller AL, Crismon ML (1999). Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 12: 179-188.
4. Centorrino F, Eakin M, Bahk W-M, Kelleher JP, Goren J, Salvatore P, Egli S, et al. (2002). Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 159:1932-35.
5. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ (2004). Multiple versus single antipsychotic agents for hospitalised psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161:700-706.
6. Freudenreich O, Goff DC (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106:323-330.
7. Ganguly R, Kotzan JA, Miller S, Kennedy K, Martin BC (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65:1377-1388.
8. Grohmann R, Engel RR, Geissler KH, Ruther E (2004). Psychotropic drug use in psychiatric inpatients: recent trends and changes over time - data from the AMPS study. Pharmacopsychiatry 37 (suppl 1):527-538.
9. Kane JM (2005). Management of patients with treatment-resistant schizophrenia, 128-129. In: Kane JM (editor): Optimizing Pharmacotherapy to Maximize Outcome in Schizophrenia [Academic Highlights]. J Clin Psychiatry 66: 122-133.
10. Kemp R, Hayward P, Applewhaite G, David A (1996). Compliance therapy in psychotic patients: randomised controlled trial. BMJ 312:345-349.
11. Knottnerus A, Dinant GJ (1997). Medicine based evidence, a prerequisite for evidence based medicine. BMJ 315:1109-1110.
12. Sernyak MJ, Rosenheck R (2004). Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 65:1597-1600.
13. Stahl SM (1999). Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry 60:425-426.
14. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N (2003). Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54: 55-59.
15. Ventura J, Nuechterlein KH, Subotnik L, Gutkind D, Gilbert E (2000). Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 2-item Brief Psychiatric Rating Scale. Psychiatry Res 97: 129-135.
16. WHO Collaborating Centre for Drug Statistic Methodology (2003). Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistic Methodology.